170 related articles for article (PubMed ID: 37641099)
21. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
Philbin MM; Parish C; Bergen S; Kerrigan D; Kinnard EN; Reed SE; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Alcaide ML; Metsch LR
AIDS Patient Care STDS; 2021 Jan; 35(1):23-30. PubMed ID: 33400587
[TBL] [Abstract][Full Text] [Related]
22. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
23. Ready for HIV Dual Therapy? - New Data from International HIV/AIDS Society 2017.
Yendewa GA; Salata RA
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019353
[TBL] [Abstract][Full Text] [Related]
24. "A dream come true": Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania.
Kerrigan D; Sanchez Karver T; Muraleetharan O; Savage V; Mbwambo J; Donastorg Y; Likindikoki S; Perez M; Gomez H; Mantsios A; Murray M; Beckham SW; Davis W; Galai N; Barrington C
PLoS One; 2020; 15(6):e0234666. PubMed ID: 32530939
[TBL] [Abstract][Full Text] [Related]
25. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
Mantsios A; Murray M; Karver TS; Davis W; Margolis D; Kumar P; Swindells S; Bredeek UF; García Del Toro M; Garcia Gasalla M; Rubio García R; Antela A; Hudson K; Griffith S; Kerrigan D
AIDS Behav; 2020 Dec; 24(12):3473-3481. PubMed ID: 32410051
[TBL] [Abstract][Full Text] [Related]
27. Injectable antiretroviral therapy: best practice guide for nurses providing care to people living with HIV.
Panton L
Br J Nurs; 2024 Jun; 33(11):S12-S17. PubMed ID: 38850143
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with incomplete adherence to integrase strand transfer inhibitor-containing single-tablet regimen among Japanese people living with HIV.
Kunimoto Y; Hikasa S; Ishihara M; Tsukiji M; Nobori K; Kimura T; Onishi K; Yamamoto Y; Haruta K; Kasiwabara Y; Fujii K; Fukudo M
J Pharm Health Care Sci; 2024 Jun; 10(1):27. PubMed ID: 38840139
[TBL] [Abstract][Full Text] [Related]
29. Preference for long-acting injectable for ART and PrEP among people with and without HIV: a cross-sectional study in Argentina.
Sciannameo S; Zalazar V; Spadaccini L; Duarte M; Cahn P; Aristegui I; Sued O
Ther Adv Infect Dis; 2024; 11():20499361241228341. PubMed ID: 38380160
[TBL] [Abstract][Full Text] [Related]
30. Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users' ambivalences.
Carillon S; Gallardo L; Linard F; Chakvetadze C; Viard JP; Cros A; Molina JM; Slama L
AIDS Care; 2020 May; 32(sup2):155-161. PubMed ID: 32189506
[TBL] [Abstract][Full Text] [Related]
31. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs).
Kityo C; Cortes CP; Phanuphak N; Grinsztejn B; Venter F
Clin Infect Dis; 2022 Nov; 75(Suppl 4):S549-S556. PubMed ID: 36410377
[TBL] [Abstract][Full Text] [Related]
32. Key informant views on potential acceptability and feasibility of long-acting antiretroviral treatment for HIV in Kenya.
Kaggiah A; Maina CN; Kinuthia J; Barthold D; Hauber B; Tran J; Simoni JM; Graham SM
BMC Infect Dis; 2024 Apr; 24(1):415. PubMed ID: 38641565
[TBL] [Abstract][Full Text] [Related]
33. Long-acting antiretrovirals and HIV treatment adherence.
Nachega JB; Scarsi KK; Gandhi M; Scott RK; Mofenson LM; Archary M; Nachman S; Decloedt E; Geng EH; Wilson L; Rawat A; Mellors JW
Lancet HIV; 2023 May; 10(5):e332-e342. PubMed ID: 37062293
[TBL] [Abstract][Full Text] [Related]
34. A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S.
Simoni JM; Tapia K; Lee SJ; Graham SM; Beima-Sofie K; Mohamed ZH; Christodoulou J; Ho R; Collier AC
AIDS Behav; 2020 Apr; 24(4):1226-1236. PubMed ID: 31655915
[TBL] [Abstract][Full Text] [Related]
35. Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy.
Philbin MM; Parish CL; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):263-270. PubMed ID: 32530905
[TBL] [Abstract][Full Text] [Related]
36. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.
Gandhi RT; Bedimo R; Hoy JF; Landovitz RJ; Smith DM; Eaton EF; Lehmann C; Springer SA; Sax PE; Thompson MA; Benson CA; Buchbinder SP; Del Rio C; Eron JJ; Günthard HF; Molina JM; Jacobsen DM; Saag MS
JAMA; 2023 Jan; 329(1):63-84. PubMed ID: 36454551
[TBL] [Abstract][Full Text] [Related]
37. Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States.
McCrimmon T; Collins LF; Perez-Brumer A; Bazzi AR; Shaffer VA; Kerrigan D; Alcaide ML; Philbin MM
AIDS Patient Care STDS; 2024 Feb; 38(2):61-69. PubMed ID: 38381949
[TBL] [Abstract][Full Text] [Related]
38. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
39. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
Blair HA
Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
[TBL] [Abstract][Full Text] [Related]
40. The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy.
Dubé K; Eskaf S; Evans D; Sauceda J; Saberi P; Brown B; Averitt D; Martel K; Meija M; Campbell D; Barr L; Kanazawa J; Perry K; Patel H; Luter S; Poteat T; Auerbach JD; Wohl DA
AIDS Res Hum Retroviruses; 2020 Apr; 36(4):324-348. PubMed ID: 31608651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
